Literature DB >> 30278171

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma?

Samuel Kim1, David A Bull2, Linda Garland3, Zain Khalpey2, Baldasarre Stea4, Sun Yi4, Charles C Hsu4.   

Abstract

BACKGROUND: Benefits of surgical resection for early-stage nonepithelioid malignant pleural mesothelioma (MPM) have not been clearly elucidated. This study investigated whether cancer-directed surgery affects overall survival compared with nonsurgical therapies for T1-T2 N0 M0 sarcomatoid or biphasic MPM patients.
METHODS: Adult patients with clinical stage I or II MPM were identified in the National Cancer Database from 2004 to 2103. Patients who underwent cancer-directed surgery were matched by propensity score with patients who had received chemotherapy/radiotherapy or no treatments. Overall survival was compared using a Cox proportional hazard regression model.
RESULTS: From National Cancer Database queries, 878 patients with clinical stage I or II MPM with sarcomatoid (n = 524) or biphasic (n = 354) histology were identified. Overall median survival was 5.5 months for patients with sarcomatoid mesothelioma. The cancer-directed surgery improved overall survival compared with no operation (median survival, 7.56 months vs 4.21 months, respectively; p < 0.01). In the biphasic group, median overall survival was 12.2 months. Again, the cancer-directed surgery improved survival compared with no operation (15.8 months vs 9.3 months, p < 0.01). For both histologies, the cancer-directed surgery improved overall survival compared with those who underwent chemotherapy or radiotherapy, or both, without resection (p < 0.05). Perioperative mortality was 6.0% at 30 days and 21.4% at 90 days.
CONCLUSIONS: The cancer-directed surgery is associated with improved survival in early-stage MPM patients with nonepithelioid histology compared with those who did not undergo resection or chose medical therapy. Given the high perioperative mortality, a careful patient selection and multidisciplinary evaluation is recommended.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30278171     DOI: 10.1016/j.athoracsur.2018.07.081

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.

Authors:  Grazia Graziani; Lucia Lisi; Lucio Tentori; Pierluigi Navarra
Journal:  Exp Suppl       Date:  2022

Review 2.  Current status and progress in immunotherapy for malignant pleural mesothelioma.

Authors:  Boyang Sun; Yiting Dong; Jiachen Xu; Zhijie Wang
Journal:  Chronic Dis Transl Med       Date:  2022-03-31

Review 3.  A Review of Pharmacologic Management in the Treatment of Mesothelioma.

Authors:  Eric P Borrelli; Conor G McGladrigan
Journal:  Curr Treat Options Oncol       Date:  2021-01-12

4.  The Construction and Analysis of ceRNA Network and Patterns of Immune Infiltration in Mesothelioma With Bone Metastasis.

Authors:  Runzhi Huang; Jiawen Wu; Zixuan Zheng; Guanghua Wang; Dianwen Song; Penghui Yan; Huabin Yin; Peng Hu; Xiaolong Zhu; Haiyun Wang; Qi Lv; Tong Meng; Zongqiang Huang; Jie Zhang
Journal:  Front Bioeng Biotechnol       Date:  2019-10-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.